美国二代雄激素受体通路抑制剂一线治疗前列腺癌的使用模式
一线达罗他胺使用持续上升,2023年达42%并超过恩扎卢胺;一线ARPI选择在地区、城乡、保险或转移状态间无显著差异。总体ARPI使用增长21倍,恩扎卢胺仍为最常用药物。
要点
- 2023年一线达罗他胺占比升至42%并超过恩扎卢胺。
- 一线ARPI选择在地区、城乡、保险及转移状态间无显著差异。
- 总体ARPI使用增长21倍,恩扎卢胺仍为最常用药物。
核心结论
- 达罗他胺到2023年迅速成为一线最常选择的ARPI,未观察到患者人口学特征的一致差异。
- 恩扎卢胺在总体处方中仍占主导,可能反映传统治疗的持续性,尤其在城市外和非转移人群。
研究设计与样本
- 使用Merative MarketScan数据库识别2012至2023年接受恩扎卢胺、阿帕他胺或达罗他胺的前列腺癌患者。
- 采用描述性分析评估年度一线启动比例和总体使用,并使用卡方检验和多变量模型比较地区、城乡、保险计划和转移状态。
主要发现
- 一线达罗他胺使用持续上升,2023年达42%并超过恩扎卢胺。
- 一线ARPI选择在地区、城乡、保险或转移状态间无显著差异。
- 总体ARPI使用在研究期间增长21倍,恩扎卢胺仍为最常见药物。
- 2023年达罗他胺处方在都市区比例更高(p=0.0008),在转移患者中比例更高(p=0.0058)。
临床怎么用
- 真实世界中达罗他胺作为一线ARPI的使用快速增加,临床选择可参考此趋势。
- 恩扎卢胺在总体处方中仍占主导,尤其在城市外和非转移人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Second-generation androgen receptor pathway inhibitors (ARPIs) have transformed treatment for patients with advanced prostate cancer. Despite overlapping indications and comparable efficacy among these ARPIs, their staggered market entry and differing toxicity profiles may influence real-world prescribing. We characterized temporal trends and utilization patterns of these agents as frontline treatment for advanced prostate cancer in the United States. METHODS: Using the Merative MarketScan database, we identified patients with prostate cancer receiving enzalutamide, apalutamide, or darolutamide between 2012 and 2023. ARPI therapy was classified as first-line if initiated after ≥180 days of continuous enrollment. Annual proportions of first-line initiation and overall utilization of ARPIs were assessed descriptively. Comparisons by geographic status, urbanicity, insurance plan, and metastatic status were evaluated using chi-squared testing and multivariable modeling. RESULTS: Among 1.1 million individuals with prostate cancer, 3773 patients received ARPI therapy, of whom 1914 met criteria for first-line analysis. Use of first-line darolutamide steadily increased, rising to 42% in 2023 and surpassing enzalutamide. First-line ARPI selection did not differ significantly by region, urbanicity, insurance, or metastatic status. Overall ARPI utilization increased 21-fold over the study period, with enzalutamide remaining the most common agent. In 2023, a higher proportion of darolutamide fills occurred in metropolitan areas (p = 0.0008), and among metastatic patients (p = 0.0058). CONCLUSION: Darolutamide rapidly emerged as the most selected first-line ARPI by 2023, without consistently observed differences by patient demographics. However, continued dominance of enzalutamide for overall fills may highlight durability of legacy therapy, particularly among non-metropolitan and non-metastatic populations.
引用
- Weitzner AS, Lokeshwar SD, Cronin C, et al. Utilization patterns of second-generation androgen receptor pathway inhibitors as first-line therapy for prostate cancer in the United States. Prostate Cancer Prostatic Dis. 2026. PMID: 42601396. doi:10.1038/s41391-026-01146-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。